Autolus Therapeutics plc
AUTL · XNASCIK 1730463fmd_1WGX7E6V413V0BAPAM2ZBZDA8VManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Oct 01, 2015 to Sep 30, 2026, 36 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 1 | 2 | 1 | 3 | – | – | – | 2 | 10 | 75 |
| Cost of revenue | – | – | – | – | – | – | – | 0 | 11 | 96 |
| Gross profit | – | – | – | – | – | – | – | 2 | (1) | (21) |
| Research and development | 10 | 16 | 36 | 105 | 135 | 111 | 117 | 130 | 138 | 118 |
| Selling, general and administrative | – | – | – | – | – | – | – | 47 | 102 | 132 |
| Total operating expenses | 14 | 23 | 58 | – | – | – | – | – | – | – |
| Operating income | – | – | – | (146) | (168) | (141) | (143) | (180) | (241) | (271) |
| Interest expense | – | – | – | 0 | 0 | 1 | 9 | 45 | 9 | 37 |
| Interest and investment income | 0 | 0 | 2 | 3 | 1 | 0 | 2 | 14 | 32 | 19 |
| Other non-operating income (expense) | 0 | 0 | 6 | 7 | 2 | (1) | (5) | (29) | 22 | (15) |
| Income before taxes | (14) | (23) | (52) | (139) | (166) | (142) | (149) | (208) | (219) | (286) |
| Income tax expense | (2) | (4) | (7) | (15) | (24) | 0 | 0 | (0) | 2 | 2 |
| Net income from continuing operations | (13) | (20) | (45) | (124) | (142) | (142) | (149) | (208) | (221) | (288) |
| Net income | (13) | (20) | (45) | (124) | (142) | (142) | (149) | (208) | (221) | (288) |
| Net income to common shareholders | – | – | – | – | (142) | (142) | (149) | (208) | (221) | (288) |